These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25061571)

  • 1. Impact of Enzyme Replacement Therapy and Hematopoietic Stem Cell Therapy on Growth in Patients with Hunter Syndrome.
    Patel P; Suzuki Y; Tanaka A; Yabe H; Kato S; Shimada T; Mason RW; Orii KE; Fukao T; Orii T; Tomatsu S
    Mol Genet Metab Rep; 2014; 1():184-196. PubMed ID: 25061571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of daily living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation.
    Tanjuakio J; Suzuki Y; Patel P; Yasuda E; Kubaski F; Tanaka A; Yabe H; Mason RW; Montaño AM; Orii KE; Orii KO; Fukao T; Orii T; Tomatsu S
    Mol Genet Metab; 2015 Feb; 114(2):161-9. PubMed ID: 25468646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic Stem Cell Transplantation for Patients with Mucopolysaccharidosis II.
    Kubaski F; Yabe H; Suzuki Y; Seto T; Hamazaki T; Mason RW; Xie L; Onsten TGH; Leistner-Segal S; Giugliani R; Dũng VC; Ngoc CTB; Yamaguchi S; Montaño AM; Orii KE; Fukao T; Shintaku H; Orii T; Tomatsu S
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1795-1803. PubMed ID: 28673849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome.
    Tomatsu S; Sawamoto K; Alméciga-Díaz CJ; Shimada T; Bober MB; Chinen Y; Yabe H; Montaño AM; Giugliani R; Kubaski F; Yasuda E; Rodríguez-López A; Espejo-Mojica AJ; Sánchez OF; Mason RW; Barrera LA; Mackenzie WG; Orii T
    Drug Des Devel Ther; 2015; 9():1937-53. PubMed ID: 25897204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy-type related long-term outcomes in mucopolysaccaridosis type II (Hunter syndrome) - Case series.
    Zerjav Tansek M; Kodric J; Klemencic S; Boelens JJ; van Hasselt PM; Drole Torkar A; Doric M; Koren A; Avcin S; Battelino T; Groselj U
    Mol Genet Metab Rep; 2021 Sep; 28():100779. PubMed ID: 34258227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Options for Mucopolysaccharidosis II (Hunter Disease).
    Kubaski F; Vairo F; Baldo G; de Oliveira Poswar F; Corte AD; Giugliani R
    Curr Pharm Des; 2020; 26(40):5100-5109. PubMed ID: 33138761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan.
    Tanaka A; Okuyama T; Suzuki Y; Sakai N; Takakura H; Sawada T; Tanaka T; Otomo T; Ohashi T; Ishige-Wada M; Yabe H; Ohura T; Suzuki N; Kato K; Adachi S; Kobayashi R; Mugishima H; Kato S
    Mol Genet Metab; 2012 Nov; 107(3):513-20. PubMed ID: 23022072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of recombinant human growth hormone on changes in height, bone mineral density, and body composition over 1-2 years in children with Hurler or Hunter syndrome.
    Polgreen LE; Thomas W; Orchard PJ; Whitley CB; Miller BS
    Mol Genet Metab; 2014 Feb; 111(2):101-6. PubMed ID: 24368158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of early haematopoietic stem cell transplantation versus enzyme replacement therapy on neurological progression in severe Hunter syndrome: Case report of siblings and literature review.
    Sreekantam S; Smith L; Stewart C; Kearney S; Lawson S; Raiman J; Vijay S; Santra S
    Mol Genet Metab Rep; 2022 Sep; 32():100881. PubMed ID: 35663302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
    Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y
    Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of enzyme replacement therapy on linear growth in Korean patients with mucopolysaccharidosis type II (Hunter syndrome).
    Cho SY; Huh R; Chang MS; Lee J; Kwun Y; Maeng SH; Kim SJ; Sohn YB; Park SW; Kwon EK; Han SJ; Jung J; Jin DK
    J Korean Med Sci; 2014 Feb; 29(2):254-60. PubMed ID: 24550654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Growth patterns in children with mucopolysaccharidosis type I-Hurler after hematopoietic stem cell transplantation: Comparison with untreated patients".
    Cattoni A; Chiaraluce S; Gasperini S; Molinari S; Biondi A; Rovelli A; Parini R
    Mol Genet Metab Rep; 2021 Sep; 28():100787. PubMed ID: 34408967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presentation and Treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome).
    Stapleton M; Kubaski F; Mason RW; Yabe H; Suzuki Y; Orii KE; Orii T; Tomatsu S
    Expert Opin Orphan Drugs; 2017; 5(4):295-307. PubMed ID: 29158997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucopolysaccharidoses I and II: Brief Review of Therapeutic Options and Supportive/Palliative Therapies.
    Nan H; Park C; Maeng S
    Biomed Res Int; 2020; 2020():2408402. PubMed ID: 33344633
    [No Abstract]   [Full Text] [Related]  

  • 15. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
    Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
    Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II.
    Schulze-Frenking G; Jones SA; Roberts J; Beck M; Wraith JE
    J Inherit Metab Dis; 2011 Feb; 34(1):203-8. PubMed ID: 20978944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the clinical outcomes in idursulfase-treated and untreated Filipino patients with mucopolysaccharidosis type II: data from the local lysosomal storage disease registry.
    Racoma MJC; Calibag MKKB; Cordero CP; Abacan MAR; Chiong MAD
    Orphanet J Rare Dis; 2021 Jul; 16(1):323. PubMed ID: 34289859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early enzyme replacement therapy enables a successful hematopoietic stem cell transplantation in mucopolysaccharidosis type IH: Divergent clinical outcomes in two Japanese siblings.
    Yamazaki N; Kosuga M; Kida K; Takei G; Fukuhara Y; Matsumoto H; Senda M; Honda A; Ishiguro A; Koike T; Yabe H; Okuyama T
    Brain Dev; 2019 Jun; 41(6):546-550. PubMed ID: 30755342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure.
    de Ru MH; Boelens JJ; Das AM; Jones SA; van der Lee JH; Mahlaoui N; Mengel E; Offringa M; O'Meara A; Parini R; Rovelli A; Sykora KW; Valayannopoulos V; Vellodi A; Wynn RF; Wijburg FA
    Orphanet J Rare Dis; 2011 Aug; 6():55. PubMed ID: 21831279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Early Hematopoietic Stem Cell Transplantation in Preventing Neurocognitive Decline in Mucopolysaccharidosis Type II: A Case Series.
    Selvanathan A; Ellaway C; Wilson C; Owens P; Shaw PJ; Bhattacharya K
    JIMD Rep; 2018; 41():81-89. PubMed ID: 29671225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.